Identifying Opportunity, Placing Risk - Consensus Reports on Biogen Idec Inc. and Regeneron Pharmace

Identifying Opportunity, Placing Risk - Consensus Reports on Biogen Idec Inc. and Regeneron Pharmaceuticals, Inc.

ID: 196716

(firmenpresse) - JAKARTA, INDONESIA -- (Marketwire) -- 10/26/12 -- Moments ago, introduced new coverage of Biogen Idec Inc. (NASDAQ: BIIB) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Full outlook, analysis and consensus opinion is available to readers via the links below.



The consistent delivery of accurate analyses relies solely on two factors, namely: market awareness and industry insight. Recent market drivers include a rise in new home sales to 5.7% in September to an annualized pace of 389,000 units, slightly stronger than market expectations for an increase to 385,000, recent confirmation of continued monetary stimulus and an unchanged FOMC policy and recent moderation of existing home sales in the US to 4.75 million annualized units in September 2012 from 4.83 million reported in the previous month. When it comes to discovering the right edge at the right time, all these factors play into effect. For a deeper understanding of the mechanics behind these events and how it can affect your portfolio, please refer to our email newsletter delivered to your inbox.

Investors Alliance is releasing new coverage on Biogen Idec Inc. for its current position within the health care sector. Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. A copy of this report featuring Biogen Idec Inc. (NASDAQ: BIIB) is available at: .

Investors Alliance has released research on Regeneron Pharmaceuticals, Inc. for its changing role within the consumer durables sector. Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. To access the full research report on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) we welcome investors to visit: .





What is Investors Alliance?
Imagine a community wherein investors and traders of all walks share both knowledge and experience... enabling a knowledge base vastly greater than the sum of its parts. By joining forces, the entire community experiences the wealth of information, insight and intuition into some of the best strategies available today.



Patricia Byers


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Identifying Opportunity, Placing Risk - Consensus Reports on Nyse Euronext, Inc. and The Nasdaq Omx Group, Inc. Timing Is Crucial, Upside Analysis - New Outlook on Cms Energy Corporation and Wisconsin Energy Corporation
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 26.10.2012 - 13:00 Uhr
Sprache: Deutsch
News-ID 196716
Anzahl Zeichen: 0

contact information:
Town:

JAKARTA, INDONESIA



Kategorie:

Commercial & Investment Banking



Diese Pressemitteilung wurde bisher 167 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Identifying Opportunity, Placing Risk - Consensus Reports on Biogen Idec Inc. and Regeneron Pharmaceuticals, Inc."
steht unter der journalistisch-redaktionellen Verantwortung von

Investors Alliance (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Investors Alliance



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z